Presentazione di PowerPoint

1
NERIDRONATE IN THE TREATMENT OF POSTMENOPAUSAL
OSTEOPOROSIS   V. Braga, J. Bakri, E. Battaglia,
D. Gatti, F. Colapietro, R. Prizzi, M. Rossini
and S. Adami Rheumatology Unit, University of
Verona, Italy
2
Introduction Bisphosphonates have been used
with success in the treatment of osteoporosis,
but oral therapy often lacks compliance.
3
Treatment

• The patients were randomized to receive for two
  years
• 50 mg Neridronate IV bimontly in addition to 500
  mg calcium plus 400 U vitamin D supplements daily
  (n. 39).
• Calcium vitamin D supplements alone (control
  group, n. 39).
• All patients had post-treatment a follow-up of 1
  year with Ca vit D.

4
Neridronate is an amino-bisphosphonate strictly
similar to alendronate and pamidronate
5
Study Population
6
Total AP
Neridronate 50 mg
Placebo
months
7
bone AP
2 yrs on
1 yr off
Placebo
Neridronate 50 mg
months
8
Cross laps
Placebo
Neridronate 50 mg
months
9
Lumbar spine
Neridronate 50 mg
Placebo
10
Femoral neck
Neridronate 50 mg
Placebo
11
CHANGES FROM BASELINE AFTER 2 YEARS OF
TREATMENT COMPARISON OF DIFFERENT
BISPHOSPHONATES SPINE BMD
BMD Changes
12
CHANGES FROM BASELINE AFTER 2 YEARS OF
TREATMENT COMPARISON OF DIFFERENT
BISPHOSPHONATES FEMORAL NECK BMD
BMD Changes
13

• CONCLUSION
•  IV Neridronate bimonthly might represent an
  attractive alternative to oral bisphosphonates.
• It increases BMD at least as well as the most
  powerful anti-resorbers.
• Its safety profile appears excellent.